Search
Displaying 731–740 of 851 results for “vision connection”
-
jCyte Announces Plans to Launch Phase 3 Clinical Trial of Cell Therapy for RP
Research NewsKnown as retinal progenitors, the company’s jCells® are designed to preserve photoreceptors in people with retinitis pigmentosa (RP) and other retinal diseases.
-
Ascidian to Launch Clinical Trial for Stargardt Disease RNA Editing Therapy
Research NewsACDN-01 is the only genetic medicine entering clinical development for Stargardt disease.
-
The goal of Envisioning a Path to Hope is to expand connections with eye care professionals all over the U.S. This important initiative will provide an opportunity for all of our volunteers and partners to share the Foundation with eye care professionals within their personal network.
-
IRD Community Loses Usher Syndrome Research Trailblazer William Kimberling, PhD
Beacon StoriesDr. Kimberling helped discover the identification and characterization of several genes that cause Usher syndrome.
-
Foundation Fighting Blindness and Eone Announce Partnership
Foundation NewsTogether, the Foundation Fighting Blindness and Eone are launching a new limited-edition tactile timepiece watch, the ChangeMaker.
-
Ocugen Reports Updated Results for Clinical Trial of Modifier Gene Therapy
Research NewsThe company is also launching modifier gene therapy clinical trials for GA and Stargardt disease
-
Atsena Doses First Patient in XLRS Gene Therapy Clinical Trial
Research NewsThe AAV.SPR gene delivery system used in the trial is designed to more safely reach targeted retinal cells
-
Life as a Teen with Retinitis Pigmentosa
Beacon StoriesAt a mere 15 years old, Ava Ruggiero’s world shifted when she received a diagnosis of retinitis pigmentosa. As Ava continues to find balance as a student and athlete, she discusses the challenges of navigating her diagnosis alongside her parents, Joseph and Stephanie.
-
Karen Petrou Appointed Foundation Chair Effective July 1, 2024, Upon the Retirement of David Brint
Foundation NewsSpecial Foundation Announcement from Jason Menzo
